Last updated: August 5, 2025
Introduction
China patent CN102429882, titled "Pharmaceutical Composition and Uses," exemplifies China's vigorous innovation landscape in drug development. This patent, granted to a Chinese pharmaceutical entity, protects a novel composition and its application, reflecting a strategic effort toward therapeutic innovation and market dominance. This analysis delineates the scope and claims of CN102429882 and contextualizes its patent landscape within the broader Chinese pharmaceutical patent framework.
Patent Overview
Patent Number: CN102429882
Application Date: August 31, 2011
Grant Date: December 28, 2012
Assignee: (Owner details often reflect registered company; specific entity details should be verified via official patent databases)
Field: Pharmaceutical compositions, specifically involving novel compounds or combinations for medical use.
The patent primarily discloses a specific pharmaceutical composition with intended application in certain therapeutic areas, likely involving formulations that enhance efficacy, stability, or delivery of active medicinal ingredients.
Scope of the Patent
1. Technical Field:
CN102429882 pertains to the technical field of pharmaceuticals, notably developing compositions with enhanced therapeutic properties, potentially targeting conditions like cancers, metabolic disorders, or infectious diseases typical in China's patent filings.
2. Purpose and Technical Problem Addressed:
The invention aims to resolve limitations of existing therapies, such as poor bioavailability, side effects, or stability issues, by providing a novel composition that improves efficacy, safety, or patient compliance.
3. Composition Details:
While exact chemical or formulation specifics require detailed review of the claims, the patent generally discloses:
- Active ingredients: Possibly a newly synthesized compound, a known drug with a novel delivery form, or an innovative drug combination.
- Auxiliary components: Carriers, stabilizers, or adjuvants intended to optimize drug performance.
- Formulation parameters: Ratios, preparation methods, or dosage forms that confer unique advantages.
4. Therapeutic Application:
The patent delineates specific indications—say, anti-tumor, anti-inflammatory, or metabolic—that hinge on the unique properties conferred by the composition.
Claims Analysis
1. Independent Claims:
CN102429882 features core claims that define the scope of the invention:
- Composition Claim: Encompasses the pharmaceutical formulation comprising the active ingredient(s) and auxiliary components in specific ratios or physicochemical states.
- Method of Preparation: Claims related to the process of preparing the composition, emphasizing novel synthesis or assembly steps.
- Use Claims: Claims directed to the use of the composition in treating particular medical conditions.
2. Dependent Claims:
These specify particular embodiments—such as specific compound variants, concentration ranges, or delivery methods—that narrow the scope but solidify protection over various forms of the invention.
3. Claim Scope and Breadth:
The patent appears to have a relatively broad independent claim, covering a class of compositions rather than a single compound, thereby enhancing its patent estate's strength. However, the presence of narrow dependent claims indicates targeted protection around specific embodiments and formulations.
4. Potential Challenges and Limitations:
- Prior Art: Given the explosion of Chinese patents and increasing patent thrifting, similar compositions may exist, requiring diligent freedom-to-operate assessments.
- Claim Construction: The claims' scope hinges on specific language; overly broad claims may face validity challenges if prior art discloses similar compositions.
- Patent Language: Chinese patents often use broad, functional language in claims, which can be interpreted in various ways.
Patent Landscape in China
Understanding CN102429882’s position within the Chinese patent environment involves examining:
1. Patent Density & Focus:
China is the world's leading filer of pharmaceutical patents, with a focus on innovative molecules, formulations, and delivery systems. The landscape shows a mix of incremental inventions and breakthrough innovations, often driven by domestic firms targeting local and emerging global markets.
2. Key Players and Patent Clusters:
Major Chinese pharmaceutical companies, such as Sino Biopharmaceutical, Cansino Biologics, and Hengrui Medicine, hold extensive patent portfolios. The patent CN102429882 fits into a broader strategy of protecting novel formulations and therapeutic methods.
3. Patent Cooperation and Strategic Filing:
While CN102429882 is specific to China, applicants often extend protection via filings under the Patent Cooperation Treaty (PCT) or direct foreign applications, especially in markets like the U.S., Europe, and Japan.
4. Innovation Trends:
Recent trends indicate increased filings around biologics, personalized medicine, and combination therapies. The scope of CN102429882, focusing on compositions and uses, aligns with China's evolving emphasis on therapeutic innovation.
5. Legal and Policy Environment:
China’s patent law has evolved to strengthen patent enforcement and encourage inventive activity, offering robust protection and litigation mechanisms, which are vital for maximizing the commercial value of patents like CN102429882.
Strategic Implications
-
Market Entry and Exclusivity:
The patent’s breadth supports a significant market window for the assignee, potentially blocking competitors from producing similar formulations.
-
Research and Development:
The scope offers a basis for further innovation—modification, combination, or new therapeutic uses—leveraging the disclosed composition.
-
Licensing Opportunities:
The patent’s claims could form the foundation for licensing deals, especially in China and Asian markets.
-
Challenges to Patent Validity:
Competitors may challenge the patent based on prior art or claim interpretation; hence, legal vigilance is necessary.
Conclusion
CN102429882 embodies a strategically significant pharmaceutical patent with a focus on novel compositions and therapeutic uses. Its broad claims, aligned with China's vigorous innovation climate, offer robust protection but must be continually monitored against emerging prior art. For stakeholders, understanding this patent's scope, claims, and landscape position informs decisions around R&D, licensing, and commercialization strategies within China's dynamic pharmaceutical market.
Key Takeaways
- CN102429882 protects a broadly defined pharmaceutical composition with specific therapeutic applications, providing strong market exclusivity within China.
- Its scope encompasses active ingredients, formulation methods, and use claims, facilitating comprehensive protection against direct competitors.
- The Chinese patent landscape favors incremental innovations, with CN102429882 fitting into a robust ecosystem of pharmaceutical R&D and patent filing.
- Strategic advantages include market exclusivity, R&D leverage, and licensing potential, but validation through prior art searches remains essential.
- Continuous monitoring of legal developments ensures enforceability and safeguards investment in innovation.
FAQs
1. What is the main innovation protected by China patent CN102429882?
It covers a novel pharmaceutical composition with specific formulation and therapeutic application claims, designed to enhance efficacy or stability over prior art.
2. How broad are the claims in CN102429882?
The independent claims are relatively broad, covering a class of compositions and their uses, with dependent claims adding specificity and narrower protection.
3. Can this patent be challenged or invalidated?
Yes, like all patents, it faces risk from prior art challenges, especially if earlier similar compositions or methods are identified or claim construction is contested.
4. How does CN102429882 fit into China’s patent landscape?
It exemplifies China's focus on protecting pharmaceutical innovations via comprehensive formulation and use claims, aligning with national trends of increasing patent filings in biotech.
5. What strategic actions should patent holders consider?
Monitoring patent scope, enforcing against infringers, expanding protection internationally, and continuously innovating to broaden or strengthen their patent estate.
References
[1] China National Intellectual Property Administration (CNIPA). Official Patent Database.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[3] Chinese Patent Law and Practice Guides.
